Cannasouth’s aim is to produce premium plus cannabis-based medicine to treat and support the health of patients suffering from a variety of conditions.
Currently, Cannasouth are developing GMP (Good Manufacturing Practice) medicinal cannabis facilities, including a CEA (Controlled Environment Agriculture) sealed greenhouse for cultivation, and a GMP manufacturing facility at Midwest Pharmaceutics.
Cannasouth has submitted a range of imported, Cannasouth-branded medicinal cannabis products for registration with the New Zealand Medicinal Cannabis Agency. This is to give New Zealand patients an interim option while the GMP licensing process is underway at our facilities.
Once these facilities are GMP licensed, all of our medicinal cannabis products will be produced under strict GMP regulations here in New Zealand and will offer unique combinations and levels of cannabinoids, designed to address the differing medical needs of patients.
Our imported, Cannasouth-branded medicines will be produced under GMP as well, and in the same formulations as our future, Cannasouth manufactured product range.
If you are a Health Care Practitioner and would like to enquire about our products, which will be coming soon, or if you are interested in importing our GACP/GMP medicinal cannabis flower, GMP cannabinoid-based medicines, API’s or CBI’s, please fill out the form on our Export and Sales page.